Oslo, August 22, 2025 - Observe Medical ("the Company" or "Observe Medical")
today releases its results for the first half of 2025. The Company will host a
presentation with a trading update Tuesday, 23 September 2025.
Financial highlights
· Operating revenues amounted to NOK 11.3 million, supported by a 61% increase
in sales of the UnoMeterT product family YoY driven by the introduction of
UnoMeterT SafetiT Plus, offset by the discontinuation of the Nordic distribution
business
· Operating result before depreciation and amortisation (EBITDA) of negative
NOK 8.7 million, an improvement of 3.9 million YoY
· Result of negative NOK 19.0 million, an improvement of NOK 6.4 million YoY
During the first half year, the first major shipments of UnoMeterT Safeti Plus
reached distributors across Europe, the Middle East, and Asia, re-establishing
sales in key markets. The product has received orders from a broad range of
countries, with multiple repeat orders confirming strong market acceptance.
Subsequent events
· July 3 2025, the Company successfully completed a private placement of new
shares in the Company to raise gross proceeds of NOK 36.4 million, to be
followed by a subsequent offering.
· The Group has, through negotiations and restructuring of debt, reduced its
total debt by approximately NOK 50 million and at the same time closed the asset
transfer agreement, enabling the transfer of all UnoMeterT associated assets to
the Group.
Observe Medical invites investors, analysts, and other stakeholders to a
presentation and trading update 23 September 2025. Details regarding the time
and venue will be announced when available.
For further information, please contact:
Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com
Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com
About Observe Medical
Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.
The Company is headquartered in Oslo, Norway.
Further information is available at www.observemedical.com.